Cancers, Free Full-Text

After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontology of disease have led to targeting mutations in isocitrate dehydrogenase, FMS-like tyrosine kinase 3 (FLT3), B-cell lymphoma 2 and hedgehog pathways. Yet outcomes remain variable; especially in defined molecular and genetic subgroups such as NPM1 (Nucleophosmin 1) mutations, 11q23/KMT2A rearranged and TP53 mutations. Emerging therapies seek to address these unmet needs, and all three of these subgroups have promising new therapeutic approaches. Here, we will discuss the normal biological roles of menin in acute leukemia, notably in KMT2A translocations and NPM1 mutation, as well as current drug development. We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.

Cancer in Lymph Nodes May Help Tumors Metastasize - NCI

Mr Bhujade Parallel Computing Pdf Download - Colaboratory

Home - Free ME from Lung Cancer

Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis - The Lancet Oncology

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

from Flow Cytometry to Cytomics, Page 2

Cancer Text Magic, PDF

PDF) Treatment outcome with low-dose-rate interstitial brachytherapy in early-stage oral tongue cancers

Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease - eBioMedicine

Ovarian cancer cell fate regulation by the dynamics between saturated and unsaturated fatty acids

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer

Remission, cancer-free, no evidence of disease: What's the difference?

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

Dr 2.4.2 Dota 1 Free Download - Colaboratory